bupropion

(redirected from Aplenzin)
Also found in: Medical.

bu·pro·pi·on

 (byo͞o-prō′pē-ŏn′)
n.
A drug, C13H18ClNO, used in its hydrochloride form for the treatment of depression and as an aid in smoking cessation. It is a weak inhibitor of norepinephrine and dopamine reuptake in the central nervous system.

[bu(tyl) + propi(ophen)on(e), a ketone (propio(nic acid) + phen(yl) + -one).]

bupropion

(bjuːˈprəʊpɪɒn)
n
an antidepressant drug used to help people stop smoking
Translations

bupropion

n bupropión m
Mentioned in ?
References in periodicals archive ?
04% Retin-A Micro Gel Fenofibric Acid Delayed-Release Trilipix Delayed- Capsules, 45 mg, 135 mg Release Capsules Metformin Hydrochloride Extended-Release Glumetza Tablets USP, 500 mg, 1,000 mg Tablets Donepezil Hydrochloride Tablets, 23 mg Aricept Tablets AUGUST 2013 Bupropion Hydrobromide Extended-Re- Aplenzin IeaseTablets,174 mg, 522 mg Extended Release Tablets Naproxen and Esomeprazole Magnesium Vimovo Delayed- Delayed-ReleaseTablets, 375 mg/20 mg Release Tablets (base), 500 mg/20 mg (base) Norethindrone and Ethinyl Estradiol Tablets Ovcon-50 USP, 1 mg/0.
Our analysis indicates that the patient shares of more recently launched antidepressants, including Pfizer's Pristiq, Sanofi's Aplenzin, and Angelini Labopharm's Oleptro, are much lower than those of generic products in first- and even second-line therapydemonstrating the increasing difficulty that new products are having penetrating the MDD market.
The FDA has also cleared Aplenzin (sanofi-aventis U.